中国组织工程研究 ›› 2024, Vol. 28 ›› Issue (31): 5017-5021.doi: 10.12307/2024.718

• 干细胞基础实验 basic experiments of stem cells • 上一篇    下一篇

两种供试品不同浸提条件及作用剂量下的体外人淋巴细胞增殖实验

许建霞,付海洋,曲守方   

  1. 中国食品药品检定研究院,北京市   102629
  • 收稿日期:2023-08-04 接受日期:2023-09-11 出版日期:2024-11-08 发布日期:2024-01-22
  • 通讯作者: 付海洋,硕士,副主任药师,中国食品药品检定研究院,北京市  102629 曲守方,博士,研究员,中国食品药品检定研究院,北京市  102629
  • 作者简介:许建霞,女,1976年生,山西省运城市人,汉族,硕士,副主任技师,主要从事医疗器械的生物安全性及有效性研究。
  • 基金资助:


In vitro human lymphocyte proliferation assay under different extraction conditions and doses of two types of test samples

Xu Jianxia, Fu Haiyang, Qu Shoufang   

  1. National Institutes for Food and Drug Control, Beijing 102629, China
  • Received:2023-08-04 Accepted:2023-09-11 Online:2024-11-08 Published:2024-01-22
  • Contact: Fu Haiyang, Master, Associate chief pharmacist, National Institutes for Food and Drug Control, Beijing 102629, China Qu Shoufang, PhD, Researcher, National Institutes for Food and Drug Control, Beijing 102629, China
  • About author:Xu Jianxia, Master, Associate chief technician, National Institutes for Food and Drug Control, Beijing 102629, China

摘要:


文题释义:

体外淋巴细胞增殖实验:又称淋巴细胞转化实验,是指体外培养的T淋巴细胞在有丝分裂原或特异性抗原的刺激下发生免疫应答,细胞的数量或代谢活性会增加。淋巴细胞增殖实验被广泛应用于药物过敏研究,在动物源性医疗器械的免疫原性研究中也占有重要地位,属于较为敏感的功能性检验方法。
植物血凝素:是发现于植物特别是豆科植物中的凝集素,属于高分子糖蛋白类,是低聚糖和蛋白质的复合物,具有促进有丝分裂的活性。


背景:体外淋巴细胞增殖实验常用于检测医疗器械潜在的免疫原性,但在相关标准中均未给出详尽的浸提条件及作用剂量。

目的:考察供试品不同浸提条件及作用剂量对体外人淋巴细胞增殖的影响,思考在选择体外淋巴细胞增殖实验条件时需考虑的因素。
方法:实验检测同种骨修复材料与肝素修饰人工晶状体两种供试品,均分为以下12组:①实验组1:供试品24 h完全培养基(含体积分数10%胎牛血清的RPMI改良培养基)浸提液200 µL+淋巴细胞悬液50 µL;②阴性对照组1:24 h完全培养基200 µL+淋巴细胞悬液50 µL;③实验组2:供试品24 h完全培养基浸提液100 µL+淋巴细胞悬液100 µL;④阴性对照组2:24 h完全培养基100 µL+淋巴细胞悬液100 µL;⑤实验组3:供试品72 h RPMI改良培养基浸提液(实验前加体积分数10%胎牛血清)200 µL+淋巴细胞悬液50 µL;⑥阴性对照组3:72 h RPMI改良培养基(实验前加体积分数10%胎牛血清)200 µL+淋巴细胞悬液50 µL;⑦实验组4:供试品72 h RPMI改良培养基浸提液(实验前加体积分数10%胎牛血清)100 µL+淋巴细胞悬液100 µL;⑧阴性对照组4:72 h RPMI改良培养基(实验前加体积分数10%胎牛血清)100 µL+淋巴细胞悬液100 µL;⑨阳性对照组1:含10 μg/mL植物血凝素M的完全培养基200 µL+淋巴细胞悬液50 µL;⑩阳性对照组2:含10 μg/mL植物血凝素M的完全培养基100 µL+淋巴细胞悬液100 µL;⑪空白对照组1:250 µL完全培养基;⑫空白对照组2:200 µL完全培养基。培养3 d后,采用CCK-8法检测淋巴细胞增殖。

结果与结论:①不同实验条件下,同种骨修复材料浸提液均可增强人淋巴细胞的活性,以RPMI改良培养基浸提72 h、浸提液与淋巴细胞悬液的体积比为4∶1的实验条件最为显著;肝素修饰人工晶状体在该条件下对淋巴细胞活性有明显的抑制作用,可能与浸提液中的肝素有关,但在完全培养基浸提24 h、浸提液与淋巴细胞悬液的体积比为4∶1的实验条件下对淋巴细胞活性有轻微的增强作用;②供试品不同浸提条件及作用剂量下,人体外淋巴细胞增殖实验结果可能会有较大差异,实验条件的选择需结合产品临床应用情况,也需考虑产品的固有特性。 

https://orcid.org/0000-0003-4883-543X (许建霞) 

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

关键词: 体外人淋巴细胞增殖, 不同实验条件, 浸提液, 同种骨修复材料, 肝素修饰人工晶状体

Abstract: BACKGROUND: In vitro lymphocyte proliferation test is often used to detect the potential immunogenicity of medical devices, but no detailed extraction conditions and dose are given in the relevant standards. 
OBJECTIVE: To investigate the effects of different extraction conditions of the test product and different doses of the extract on in vitro human lymphocyte proliferation, and to consider the factors that need to be considered when selecting test conditions for in vitro lymphocyte proliferation test. 
METHODS: In the experiment, the homogenous bone repair material and heparin-modified intraocular lens were divided into the following 12 groups: (1) Experimental group 1: 24-hour complete medium (RPMI modified medium containing 10% fetal bovine serum) extract of 200 µL + lymphocyte suspension of 50 µL; (2) negative control group 1: 24-hour complete medium 200 µL + lymphocyte suspension 50 µL; (3) experimental group 2: 24-hour complete medium extract 100 µL + lymphocyte suspension 100 µL; (4) negative control group 2: 24-hour complete medium 100 µL + lymphocyte suspension 100 µL; (5) experimental group 3: 72-hour RPMI modified medium extract (addition of 10% fetal bovine serum before experiment) 200 µL + lymphocyte suspension 50 µL; (6) negative control group 3: 72-hour RPMI modified medium (addition of 10% fetal bovine serum before experiment) 200 µL + lymphocyte suspension 50 µL; (7) experimental group 4: 72-hour RPMI modified medium extract (addition of 10% fetal bovine serum before experiment) 100 µL + lymphocyte suspension 100 µL; (8) negative control group 4: 72-hour RPMI modified medium (addition of 10% fetal bovine serum before experiment) 100 µL + lymphocyte suspension 100 µL; (9) positive control group 1: complete medium containing 10 μg/mL plant hemagglutinin-M 200 µL + lymphocyte suspension 50 µL; (10) positive control group 2: complete medium containing 10 μg/mL plant hemagglutinin-M 100 µL + lymphocyte suspension 100 µL; (11) blank control group 1: 250 µL complete medium; (12) control group 2: 200 µL complete medium. After 3 days of culture, the proliferation of lymphocytes was detected by CCK-8 assay.
RESULTS AND CONCLUSION: (1) Under different test conditions, the extracts of the allogeneic bone repair material could enhance the activity of human lymphocytes. Under the condition of 72-hour leaching in RPMI modified medium and the volume ratio of leaching solution and lymphocyte suspension was 4:1, the most significant effect was observed. Heparin-modified intraocular lens extract also had obvious inhibitory effect on lymphocyte activity under this condition; its inhibitory effect on lymphocyte activity may be related to the heparin in the extract. However, the activity of lymphocytes was slightly enhanced by heparin-modified intraocular lens extract under the experimental conditions of complete medium extraction for 24 hours and the volume ratio of extract to lymphocyte suspension was 4:1. (2) Under different extraction conditions and doses, the results of in vitro lymphocyte proliferation test may be quite different. The selection of test conditions should be combined with the clinical application of the product, and the inherent characteristics of the product should also be considered.

Key words: in vitro human lymphocyte proliferation, different test conditions, leaching liquor, allogeneic bone repair material, heparin-modified intraocular len

中图分类号: